Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors

US11542261B2 · kind B2 · utility

Assignees

• Children's Hospital Medical Center · US
• The United States of America as Represented by the Secretary, Dept. of Health and Human Services · US

Inventors

• Daniel Starczynowski · Cincinnati, US
• Craig J. Thomas · Gaithersburg, US
• Garrett W. Rhyasen · Cincinnati, US
• Katelyn Melgar · Cincinnati, US
• Morgan MacKenzie Walker · New Haven, US
• Jian-Kang Jiang · Columbia, US

Key dates

• Filing date: Feb 28, 2020
• Grant date: Jan 3, 2023
• Expiry date: Feb 28, 2040

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K31/496
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I)) and compositions (e.g., pharmaceutical compositions) which can be used for treating, for example, certain diseases. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as head and neck squamous cell carcinoma (HNSCC), cancer, blood disorders, etc.). Additional embodiments provide synergistic combinations of a BCL2 inhibitor with an IRAK inhibiting compound, and methods of using same.